Cat. No. 2146
Chemical Name: N,N''-1,4-Butanediylbis[N'-(3-isothiocyanatophenyl)thiourea
Biological ActivitySelective antagonist of P2Y6 nucleotide receptors; IC50 values are 37 and 98 nM at human and rat P2Y6 receptors respectively. Displays no activity at P2Y1, P2Y2, P2Y4 and P2Y11 receptors (IC50 > 10 μM). Inhibits agonist-induced cardiomyocyte contraction and UDP-induced phagocytosis.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Mamedova et al (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem.Pharmacol. 67 1763. PMID: 15081875.
Koizumi et al (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446 1091. PMID: 17410128.
Kukulski et al (2007) Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo. J.Leukoc.Biol. 81 1269. PMID: 17322022.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MRS 2578, supplier, Selective, P2Y6, antagonists, Receptors, Purinergic, purinoceptors, MRS2578
Find multiple products by catalog number
New Products in this Area
CXCR3 antagonist; inhibits cell migration and metastasisGW 627368
Selective EP4 receptor competitive antagonistLUF 6283
HCA2 (GPR109A) partial agonistNS 304
Selective prostacyclin IP1 receptor agonistCYM 5541
Selective S1P3 receptor allosteric agonistTC LPA5 4
LPA5 receptor antagonistGSA 10
Smo receptor agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.